Cross-border M&A originating from developing countries (The case of the Indian pharmaceutical industry) Available to Purchase

Arsia Amir-Aslani is Program Director at Department of Management and Technology, Grenoble Ecole de Management, Grenoble, France. He is the Program Director of the Advanced Master’s degree “Biotechnology and Pharmaceutical Management” at Grenoble Ecole de Management. He is a Former Investment Banker and was Senior Marketing Executive at a health-care consultancy firm, where he provided consulting services to leading Health care companies. He has more than 18 years of experience in the Hi-technology and Biotechnology sectors from a capital market, consulting, educational and industry perspective. He holds a PhD in Biochemical Sciences from the University of Paris, Pierre et Marie- Curie, as well as a MSc in International Management from the University of Paris, Sorbonne. Furthermore, since 2009, he has been Professor of Strategy and Finance at Grenoble Ecole de Management. He has numerous publications in both academic and practitioner journals.

Mark Anthony Chanel is Affiliate Professor of Strategy and Finance at Department of Strategy and Finance, Grenoble Ecole de Management, Grenoble, France. He has more than 15 years of professional work experience in health care and technology companies, Mark Chanel is currently working as a consultant helping small and midsized companies while also teaching at several universities. Most recently Mark was the Director, Finance and Administration for a company focused on the pharmaceutical market in the USA and was also a Director in a medical device company that went through a successful initial public offering on the NASDAQ stock exchange. Mark’s areas of expertise include Finance, Human Resources, Operations, and Competitive Intelligence. He holds a BSE degree in Chemical Engineering, an MSc degree in Management Consulting, and an MBA degree in Finance. In addition, he has authored several papers dealing with Finance and Competitive Intelligence.